Popular Trials
Popular Filters
Trials With No Placebo
Janus Kinase (JAK) Inhibitor
Baricitinib for Oral Lichen Planus
This trial is testing baricitinib, a drug that might help people with painful mouth sores from Oral Lichen Planus. It aims to see if the drug can improve their condition and quality of life, and what side effects it might have. Participants will take the drug for several months and visit the clinic regularly for evaluations. Baricitinib has been evaluated for other conditions and has shown potential as a treatment.
Anti-fibrinolytic agent
Tranexamic Acid for Skin Pigmentation Disorders
This trial is testing tranexamic acid, a medication that can lighten dark patches on the skin, on patients with lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). These patients have not found consistent relief with other treatments. Tranexamic acid works by reducing inflammation and blocking processes that cause the skin to darken. It is increasingly recognized for its utility in treating various skin conditions, including melasma and post-inflammatory hyperpigmentation.
Frequently Asked Questions
Introduction to lichen planus
What are the top hospitals conducting lichen planus research?
Although lichen planus may not be as widely known as some other medical conditions, hospitals worldwide are actively engaged in clinical trials to better understand and treat this dermatological disorder. In Laguna Hills, Orange Coast Women's Medical Group takes on the challenge with one ongoing trial dedicated to lichen planus. Similarly, Weill Cornell Dermatology in New york is making strides with their own active trial for this condition. Delricht Research - Touro Medical Center in New Orleans has also joined the effort, conducting their first recorded lichen planus trial in 2022. Further contributing to advancements in treatment options is Clinohio Research Services located in Columbus and Wiseman Dermatology Research Inc based out of Winnipeg; both clinics have launched a single active clinical trial each for lichen planus.
Lichen planus is an inflammatory skin disease that can manifest as itchy, flat-topped bumps or lesions on various parts of the body including the skin, mouth, nails, and genitals. Though its exact cause remains unknown, researchers believe it may involve an autoimmune response triggered by certain medications or viral infections such as hepatitis c.
These hospitals' commitment to investigating lichen planus reflects a broader dedication within the medical community to unravel its mysteries and develop effective treatments. By studying new therapies through clinical trials—vigilantly monitoring patient outcomes—these institutions strive towards improving quality of life for those living with lichen planus while potentially uncovering breakthroughs that could influence future dermatological practices globally
Which are the best cities for lichen planus clinical trials?
For individuals seeking clinical trials for lichen planus, several cities offer promising options. In New york, there are two active trials investigating treatments like KeryFlex and Ruxolitinib cream. Baton Rouge, Louisiana also presents two ongoing studies focusing on Ruxolitinib cream and other interventions. Additionally, Laguna Hills, California has one active trial centred around feasibility and potential solutions for lichen planus. Another city to consider is New Orleans, Louisiana with a single trial exploring the effectiveness of Ruxolitinib cream among other approaches. Lastly, Columbus, Ohio offers one active trial researching the same treatment options as mentioned previously. These cities provide opportunities for individuals with lichen planus to participate in clinical trials that could lead to improved management strategies and better outcomes for this condition
Which are the top treatments for lichen planus being explored in clinical trials?
Clinical trials are driving the search for effective treatments for lichen planus, with several promising options on the horizon. Leading the pack is KeryFlex, a cutting-edge treatment currently being explored in one active trial dedicated to tackling this condition. Also showing promise is Ruxolitinib cream, which has garnered attention in one ongoing clinical trial since its introduction in 2022. Another potential contender is Ixekizumab Auto-Injector, making waves with its inclusion in one active trial after first being listed as a treatment option in 2021. Lastly, Tranexamic acid tablets offer hope as they undergo investigation in one active trial following their debut on the scene in 2020. These innovative therapies hold great potential for transforming the landscape of lichen planus management and improving outcomes for patients worldwide
What are the most recent clinical trials for lichen planus?
Exciting advancements are taking place in the field of lichen planus research, with recent clinical trials offering potential relief for those affected by this condition. One promising trial focuses on the use of ruxolitinib cream, which has entered Phase 2 and became available on 11/23/2022. Another study explores the effectiveness of tranexamic acid tablets in treating lichen planus, also in Phase 2 and accessible since 3/17/2020. Finally, apremilast is being evaluated as a potential treatment option for lichen planus patients through a Phase 2 trial that began on 2/1/2010. These ongoing trials provide hope for improved management strategies and enhanced quality of life for individuals living with lichen planus.
What lichen planus clinical trials were recently completed?
A recent clinical trial investigating potential treatments for lichen planus has reached a significant milestone. In December 2020, the University of California, San Francisco completed a trial evaluating the efficacy of dexamethasone 0.5mg/5ml solution in Mucolox™. This study contributes to our understanding of possible therapies for lichen planus and highlights ongoing efforts to improve treatment options for individuals affected by this condition.